secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001213900-25-119439
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro Holdings granted Nasdaq extension to regain listing compliance
--------------------------------------------------------------------

- Received extension from Nasdaq Hearings Panel to achieve full compliance; deadline not specified.
- Completed reverse stock split on Nov 3; plans to increase stockholders' equity and may transfer markets.
- Has access to up to $44M in equity financing to fund operations and milestones through 2026.
- Achieved ~60% reduction in operating expenses vs prior year; lead candidate ABP-102 on track for 2026 first-in-human trials.
- Lead candidate ABP-102 developed with Celltrion; DiversImmune and MultiMab platforms advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025119439/0001213900-25-119439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025119439/ea0268922-8k_abpro.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-119439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer